Diagnostics and Therapeutics For Glaucoma

Abstract

Methods and compositions for diagnosing and treating glaucoma are disclosed.

1 - 29 . (canceled) 
     
     
         30 . A method for treating glaucoma in a human subject, comprising administering to the subject, a therapeutically effective amount of a compound that modulates the level or bioactivity of a Wnt pathway component or frizzled related protein gene product. 
     
     
         31 - 33 . (canceled) 
     
     
         34 . The method of  claim 30 , wherein the compound is an antagonist of a frizzled related protein gene product. 
     
     
         35 . The method of  claim 34 , wherein the compound is a gene therapeutic. 
     
     
         36 . The method of  claim 34 , wherein the compound is a protein therapeutic. 
     
     
         37 . The method of  claim 30 , wherein the compound is an agent that increases the level of a Wnt pathway component gene or bioactivity. 
     
     
         38 . A method of  claim 30 , wherein the compound is comprised of an antagonist of a mutant frizzled related protein gene or gene product. 
     
     
         39 . A method of  claim 38 , wherein the compound is an antisense, ribozyme or triple helix molecule. 
     
     
         40 . A method of  claim 38 , wherein the compound is a small molecule, peptide, or peptidomimetic. 
     
     
         41 . A method of  claim 38 , wherein the compound is an antibody. 
     
     
         42 - 43 . (canceled) 
     
     
         45 . The method of  claim 30 , wherein the Wnt pathway component is a Frizzled gene product, a beta-catenin gene product, a T-Cell Factor (TCF) gene product, a T-Cell Factor (TCF) regulated gene product, a glycogen synthase-kinase gene product, or a protein kinase C gene product. 
     
     
         46 . The method of  claim 45 , wherein the compound increases the level or bioactivity of a Frizzled gene product, a beta-catenin gene product, a T-Cell Factor (TCF) gene product or a T-Cell Factor (TCF) regulated gene product. 
     
     
         47 . The method of  claim 45 , wherein the compound decreases the level or bioactivity of a frizzled related protein gene product, a glycogen synthase-kinase gene product, or a protein kinase C gene product.